Rapid Fire Rounds - Multiple Myeloma Management with Dr. Joseph Mikhael
From Oncology Brothers: Practice-Changing Cancer Discussions · · 25 min
This plays from the publisher's own server. We do not host a copy.
Description
Welcome to the Oncology Brothers podcast and our new series, Rapid Fire Rounds! In this episode, we were joined by Dr. Joseph Mikhael, a myeloma specialist from the City of Hope, to answer 10–12 community-sourced questions on multiple myeloma management.
The panel covers:
- Frontline therapy: Quadruplet therapy, carfilzomib vs bortezomib, and high-risk disease definitions
- Maintenance strategies: Lenalidomide alone vs daratumumab-lenalidomide vs carfilzomib-lenalidomide, with insights from the ENDURANCE, ATLAS trials
- Relapsed/refractory disease: Sequencing CAR T-cell therapy, bispecific antibodies (teclistamab + daratumumab), and the newly approved cereblon modulators (CELMoDs) like mezigdomide
- CAR-T logistics: The critical distinction between holding therapy (pre-collection) and bridging therapy (post-collection)
- Supportive care: IVIG, antiviral/antifungal prophylaxis, and monitoring for ICANS
- MRD testing: Current role in clinical practice and its use as an endpoint for drug approval
This episode is packed with practical, actionable insights for community oncologists managing myeloma day-to-day.
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
Follow us on social media:
- X/Twitter: https://x.com/oncbrothers
- Instagram: https://www.instagram.com/oncbrothers
- Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more Rapid Fire Rounds from the Oncology Brothers!
#MultipleMyeloma, #CARTtherapy, #MRD, #CELMoD, #OncologyBrothers
Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem